- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07604610
Epicardial Fat Tissue and Cardiometabolic Risk in Russian and Asian Populations (EPIGRAPH)
Epicardial Fat Tissue Assessed by Echocardiography in Russian and Asian Populations: Association With Chronic Non-Communicable Diseases and Risk Factors
Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling.
According to the literature, increased EFT thickness is associated with a wide range of NCDs, disease severity, and prognosis.
The aim of this study is to investigate the associations between EFT thickness and clinical and anamnestic parameters, as well as to evaluate the prognostic value of this parameter in patients aged 50-70 years from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan.
Study Overview
Status
Detailed Description
The study is designed to:
- Assess physical examination findings, laboratory parameters, and comorbidities;
- Evaluate transthoracic echocardiography parameters;
- Analyze associations between EFT thickness and clinical and anamnestic characteristics;
- Determine threshold values of EFT thickness associated with structural and functional myocardial remodeling;
- Conduct follow-up via telephone to assess study endpoints;
- Evaluate the prognostic value of EFT thickness with respect to a composite endpoint.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Olga Dzhioeva, MD, Associate Professor
- Phone Number: +79166141821
- Email: odzhioeva@gnicpm.ru
Study Contact Backup
- Name: Elizaveta Rogozhkina, PhD
- Phone Number: +79371047331
- Email: lizarogozkina@gmail.com
Study Locations
-
-
-
Moscow, Russia
- Recruiting
- National Medical Research Center for Therapy and Preventive Medicine
-
Contact:
- Olga Dzhioeva, MD, Associate Professor
- Phone Number: +79166141821
- Email: odzhioeva@gnicpm.ru
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 50-70 years undergoing transthoracic echocardiography in inpatient or outpatient settings;
- Ability and willingness to provide informed consent.
Exclusion Criteria:
- Refusal to sign informed consent;
- Inability to perform transthoracic echocardiography or poor image quality;
- Severe psychiatric disorders.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Observational cohort
Patients aged 50-70 years undergoing transthoracic echocardiography (TTE) in inpatient or outpatient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Composite endpoint - all-cause mortality - hospitalizations - major adverse cardiovascular events (MACE)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-02/26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visceral Obesity
-
20LighterCompletedHypertension | Obesity | Dyslipidemias | Type 2 Diabetes | Obesity, Morbid | Metabolic Disease | Visceral Obesity | Obesity, Visceral | Central Obesity
-
Medical University of BialystokCompleted
-
United Arab Emirates UniversityUnknownVisceral ObesityUnited Arab Emirates
-
Region VästerbottenUmeå UniversityUnknown
-
CAPENERGY MEDICAL, SLUniversity of Malaga; Alfonso X El Sabio UniversityCompletedObesity; Endocrine | Obesity, VisceralSpain
-
National and Kapodistrian University of AthensCompletedBody Weight | Visceral ObesityGreece
-
Goztepe Prof Dr Suleyman Yalcın City HospitalCompleted
-
FauquéInstitut Polyclinique de Cannes (IPOCA)CompletedObesity | Female | Obesity, Abdominal | Obesity, VisceralFrance
-
University of Texas Southwestern Medical CenterNovo Nordisk A/SCompletedCardiovascular Diseases | Fat Disorder | Obesity, VisceralUnited States
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity, VisceralUnited States